Your browser doesn't support javascript.
loading
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing, S; Wirapati, P; Lenz, H-J; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, D P; Jung, A; Kirchner, T; Aderka, D; Tejpar, S; Heinemann, V.
Afiliación
  • Stintzing S; Department of Medicine, Division of Hematology, Oncology, and Tumor Immunology (CCM), Charité Universitaetsmedizin Berlin, Berlin, Germany. Electronic address: sebastian.stintzing@charite.de.
  • Wirapati P; SIB Swiss Institute of Bioinformatics, Bioinformatic Core Facility, Lausanne, Switzerland.
  • Lenz HJ; USC Norris Comprehensive Cancer Center, Los Angeles, USA.
  • Neureiter D; Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria.
  • Fischer von Weikersthal L; Gesundheitszentrum St. Marien, Amberg.
  • Decker T; Oncological Practice, Ravensburg.
  • Kiani A; Medizinische Klinik IV, Klinikum Bayreuth, Bayreuth.
  • Kaiser F; VK&K Studien GbR, Landshut.
  • Al-Batran S; Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt/Main.
  • Heintges T; Department of Medicine II, Städtisches Klinikum Neuss, Neuss.
  • Lerchenmüller C; Oncological Practice, Münster.
  • Kahl C; Haematology and Oncology, Staedtisches Klinikum Magdeburg, Magdeburg.
  • Seipelt G; Oncological Practice, Bad Soden.
  • Kullmann F; Department of Medicine I, Klinikum Weiden, Weiden.
  • Moehler M; University Hospital Mainz, Mainz, Germany.
  • Scheithauer W; Department of Internal Medicine I & Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.
  • Held S; ClinAssess GmbH, Leverkusen.
  • Modest DP; Department of Medicine III, University Hospital, LMU Munich, Munich.
  • Jung A; Institute of Pathology University of Munich, Munich, Germany.
  • Kirchner T; Institute of Pathology University of Munich, Munich, Germany.
  • Aderka D; Department of Gastrointestinal Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
  • Tejpar S; Molecular Digestive Oncology, UZ Leuven, Belgium.
  • Heinemann V; Department of Medicine III, University Hospital, LMU Munich, Munich.
Ann Oncol ; 30(11): 1796-1803, 2019 11 01.
Article en En | MEDLINE | ID: mdl-31868905
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Bevacizumab / Cetuximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Bevacizumab / Cetuximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article